Suppr超能文献

保钾利尿剂(螺内酯、氨苯蝶啶、阿米洛利)

[Potassium-sparing diuretics (spironolactone, triamterene, amylorid)].

作者信息

Haris A, Radó J

机构信息

Fövárosi Uzsoki utcai Kórház, Nephrologia-Hypertonia 3.sz. Belgyógyászati Osztály.

出版信息

Orv Hetil. 1996 Sep 1;137(35):1907-14.

PMID:8927344
Abstract

The group of drugs, so-called "potassium sparing diuretics" represent an important part of our modern therapeutic arsenal. Their "weak diuretic" properties are especially beneficial in cirrhotic patients with ascites, when highly effective loop diuretics may be hazardous. Potassium sparing diuretics have not only the advantage of avoiding potassium loss, but can potentiate the effects of diuretics acting in distal tubules and Henle's loop also. They may be combined by each other or ACE inhibitors too, taking the necessary precautions and laboratory monitoring. Their indications include the hypertension and special diseases as Conn's, Bartter's, Liddle syndromes and hirsutism. The broad clinical usefulness justifies the drug inventory ambition to develop new, more effective potassium sparing compounds without side effects. Authors overview their main clinicofarmacological properties, therapeutical indications alone or in combinations and their potential side effects.

摘要

所谓的“保钾利尿剂”这一类药物是现代治疗手段的重要组成部分。它们的“弱利尿”特性对伴有腹水的肝硬化患者尤为有益,此时高效的袢利尿剂可能具有危险性。保钾利尿剂不仅具有避免钾流失的优势,还能增强作用于远曲小管和髓袢的利尿剂的效果。它们彼此之间或与血管紧张素转换酶抑制剂联合使用时,需采取必要的预防措施并进行实验室监测。其适应证包括高血压以及诸如原发性醛固酮增多症、巴特综合征、利德尔综合征和多毛症等特殊疾病。广泛的临床实用性证明了开发新的、更有效的无副作用保钾化合物的药物研发目标是合理的。作者概述了它们主要的临床药理学特性、单独或联合使用时的治疗适应证以及潜在的副作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验